Enbrel 25 mg solution for injection in pre-filled pen *

  • Company:

    Pfizer Healthcare Ireland
  • Status:

    No Recent Update
  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)
  • Active Ingredient(s):

    *Additional information is available within the SPC or upon request to the company

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 02 June 2021

File name

DEC202136258_Adv SPC EN 40_0 25mg_50mg Pen IE clean_1622609693.pdf

Reasons for updating

  • Change to section 4.2 - Posology and method of administration

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows: Section 4.2 Detailed instructions on unintentional dosing or scheduling variations, including missed doses to refer to the PIL

Updated on 30 March 2021

File name

DEC202121880_Adv SPC EN 39_0 25mg_50mg Pen IE clean_1617131451.pdf

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 30 March 2021

File name

DEC202121880_Adv PIL EN 15_0 25 mg Pen IE clean_1617131386.pdf

Reasons for updating

  • Change to Section 1 - what the product is
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - excipient warnings
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 26 January 2021

File name

DEC202104817_Adv SPC EN 38_0 25mg_50mg Pen IE clean_1611648695.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows: Section 4.8 addition of headache as an ADR with a frequency of very common. Section 4.4 and 4.8 removal of text regarding IBD in JIA patients

Updated on 26 January 2021

File name

DEC202104817_Adv PIL EN 14_0 25 mg Pen IE clean_1611648661.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 14 September 2020

File name

DEC202060602_Adv SPC EN 37_0 25mg_50mg Pen IE clean_1600071129.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 14 September 2020

File name

DEC202060602_Adv PIL EN 13_0 25 mg Pen IE clean_1600071096.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 03 July 2020

File name

DEC202045193_Adv SPC EN 35_0 25mg_50mg Pen clean_1593770860.pdf

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows: Section 4.2 and 4.4 have been updated to refmove the work Alert from Patient Alert Card.

Updated on 03 July 2020

File name

DEC202045193_Adv PIL EN 11_0 25 mg Pen UK_IE clean_1593770819.pdf

Reasons for updating

  • Change to section 2 - excipient warnings
  • Change to section 6 - date of revision

Updated on 26 November 2019

File name

Adv PIL EN 10_0 25 mg Pen UK_IE clean_1574771068.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 26 November 2019

File name

DEC201965747_Adv SPC EN 33_0 25mg_50mg Pen UK_IE clean_1574757686.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows: Section 4.8 Addition of adverse reaction for Inflammatory bowel disease. Package Leaflet:

Updated on 23 April 2019

File name

DEC201920929_Adv PIL EN 9_0 25 mg Pen UK_IE_1556006787.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 23 April 2019

File name

DEC201920929_Adv SPC EN 33_0 25mg_50mg Pen UK_IE_1556006848.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows: Section 4.8 addition of PRAC class labelling for Lichenoid Reactions

Updated on 13 March 2019

File name

Adv SPC EN 32_0 25mg_50mg Pen UK_IE clean_1552469000.pdf

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows: Section 4.6 addition of most up-to-date information on the safe and effective use of etanercept during pregnancy.

Updated on 12 March 2019

File name

Adv PIL EN 8_0 25 mg Pen UK_IE clean_1552383195.pdf

Reasons for updating

  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 6 - date of revision

Updated on 03 August 2018

File name

Adv PIL EN 7_0 25 mg Pen UK_IE clean_1533302819.pdf

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 03 August 2018

File name

Adv SPC EN 31_0 25mg_50mg Pen UK_IE clean_1533302862.pdf

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows: Section 7 Name and address of MAH changed from Pfizer UK to Pfizer Belgium.

Updated on 01 June 2018

File name

Adv_SPC_EN_EN_30_0_25mg_50mg_Pen_UK_IE_clean.docx

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows: Date of approval, PfLEET number and internal revision number only

Updated on 10 May 2018

File name

Adv PIL EN 6_0 25 mg Pen UK_IE clean.pdf

Reasons for updating

  • Change to section 6 - date of revision

Updated on 04 April 2018

File name

PIL_17309_942.pdf

Reasons for updating

  • New PIL for new product

Updated on 04 April 2018

Reasons for updating

  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 26 February 2018

File name

PIL_17309_689.pdf

Reasons for updating

  • New PIL for new product

Updated on 26 February 2018

Reasons for updating

  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - marketing authorisation number

Updated on 05 February 2018

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 5 - how to store or dispose
  • Change to section 6 - date of revision

Updated on 05 December 2017

Reasons for updating

  • Change to section 4 - possible side effects

Updated on 25 September 2017

Reasons for updating

  • New PIL for new product
  • New PIL for medicines.ie